EGFR and non-small cell lung carcinoma: In accordance with the present results, a previous study demonstrated that the median OS of NSCLC patients who received Osimertinib was 26.8 months (95% CI, 24.0–29.1 months),[28] which seems to be longer than EGFR-TKIs and chemotherapy reported in a previous meta-analysis[7]; however, the observed difference in OS between EGFR-TKIs and chemotherapy in the 2 previous meta-analyses was not significant.[7,27] Further studies that determine the relative OS with Osimertinib versus EGFR-TKIs/chemotherapy in EGFR-mutated NSCLC will need to be performed.